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AIA = antigen-induced arthritis; AP = alkaline phosphatase; CFA = complete Freund’s adjuvant; CIA = collagen-induced arthritis; CII = collagen
type II; CLR = C-type lectin receptor; CRP = C-reactive protein; DC = dendritic cell; EAE = experimental autoimmune encephalomyelitis; HP =
hydroxylysylpyridinoline; HPLC = high-performance liquid chromatography; IFN = interferon; Ig = immunoglobulin; IL = interleukin; LP = lysylpyridi-
noline; MHC = major histocompatibility complex; OVA = ovalbumine; RA = rheumatoid arthritis; Th1 = T helper type 1; TIMP = tissue inhibitor of
metalloproteases; TLR = Toll-like receptor.
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Abstract
Models of rheumatoid arthritis (RA) in laboratory animals are
important tools for research into pathogenic mechanisms and the
development of effective, safe therapies. Rodent models (rats and
mice) have provided important information about the pathogenic
mechanisms. However, the evolutionary distance between rodents
and humans hampers the translation of scientific principles into
effective therapies. The impact of the genetic distance between
the species is especially seen with treatments based on biological
molecules, which are usually species-specific. The outbred nature
and the closer anatomical, genetic, microbiological, physiological,
and immunological similarity of nonhuman primates to humans may
help to bridge the wide gap between inbred rodent strain models
and the heterogeneous RA patient population. Here we review
clinical, immunological and pathological aspects of the rhesus
monkey model of collagen-induced arthritis, which has emerged as
a reproducible model of human RA in nonhuman primates.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease of
unknown etiology [1,2]. Once established, immune reactions
against joint components contribute significantly to the
pathological hallmarks of the disease, being synovial
hyperplasia (pannus formation) and a variable degree of
destruction and remodeling of joint cartilage and bone. RA
affects approximately 1% of people in Western countries,
with a 2:1 prevalence in females over males. The ageing
societies in the developed countries create a growing need
for safer and more effective therapies to treat chronic
diseases such as RA. The advent of biotechnology has
fuelled the search for drugs that act more specifically to
overcome the considerable side effects of nonspecific anti-
inflammatory and immunosuppressive drugs. Especially for
immune-mediated diseases, biotechnology-based therapies
have a great therapeutic potential. The preclinical develop-
ment of immunomodulatory compounds often begins with an
observation in vitro, after which proof of therapeutic principle
is obtained in animal models, usually in inbred strains of rats
or mice.
Unfortunately, the promising effects of new therapeutics
observed in rodents are often not reproduced on testing in
patients. There is a growing awareness that the evolutionary
gap between inbred rodent strains and the human population
is too wide for direct translation of data from rodents to
humans [3]. Because of the closer evolutionary and
immunological proximity to humans, nonhuman primates may
help to bridge this gap [4-6]. Trans-species antigen
presentation of human antigen-presenting cells to rhesus T
cells and vice versa [7,8] nicely illustrates the immunological
proximity of rhesus monkeys and humans [9-11].
It is of critical importance for preclinical safety testing that the
selected animal model is sensitive to the pharmacological
action of the tested drug and that the tissue distribution and
pharmacological properties of the molecules targeted by the
treatment are comparable to those observed in patients [12].
Parallel to the advent of biotechnology in recent decades, the
interest in nonhuman primate models of human disease, in
which highly specific new treatments can be tested, has
increased. It is remarkable that whereas in transplantation
research nonhuman primates are considered an essential
preclinical model in the development of new therapies, the
selection of therapies for a chronic disease such as RA relies
mainly on inbred rodent models [6]. Many new therapeutic
reagents, such as antibodies, cytokines, and cytokine
antagonists but also more specifically acting small molecules,
are active only in humans and some closely related nonhuman
primate species.
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Nonhuman primates spontaneously develop several of the
arthritic diseases that affect the human population [9,13].
However, spontaneous manifestations of arthritis in a large
outbred population of rhesus monkeys (>1,000 individuals)
kept at the Biomedical Primate Research Centre in Rijswijk
(the Netherlands) are rare. The low incidence and
unpredictable nature of spontaneous arthritis prompted us to
develop a model that can be induced at will and that is
suitable for testing new therapies for safety and efficacy.
Arthritis models in nonhuman primates
Initial attempts were aimed at the reproduction of well-
established arthritis models in rats and mice, to test whether
these were experimentally feasible and would be compatible
with ethical and practical standards. Widely used models,
such as streptococcal-cell-wall-induced or mycobacterium-
induced reactive arthritis in Lewis rats, could not be
reproduced in rhesus monkeys [14].
A frequently used model of joint inflammation in rodents is
antigen-induced arthritis (AIA). In a preliminary experiment,
intra-articular injection of methylated ovalbumin (OVA) into
OVA-sensitized rhesus monkeys induced macroscopic
arthritis in one of two monkeys (MPM Vierboom, personal
observation). The AIA model may provide a useful model,
causing less discomfort to the animals than systemic
polyarthritis, for the assessment of the immunogenic
properties of new products to assist in the repair of the joint
under local inflammatory conditions or therapeutics that are
administered locally to suppress inflammation.
The clinical expression of arthritis induced by collagen type II
(CII) in rodent strains is strongly influenced by their genetic
background [15-17]. Immunization with heterologous CII
induces reproducible autoimmune-mediated arthritis in a
variety of genetically susceptible strains of mice and rats and
in macaques [18,19]. Interestingly, immunization with bovine
CII induced spondylitis without joint involvement in Buffalo
rats (RT1b), while Wistar rats (RT1u) developed chronic joint
inflammation without marked involvement of the spinal
column. The F1 offspring of both strains developed inflam-
mation at both locations (B ‘t Hart, personal observation).
While inbred rodent strains are genetically uniform and
essentially represent a single individual in an outbred
population, an outbred colony of rhesus macaques more
closely resembles the human population in its heterogeneity.
Predictably, the incidence and clinical presentation of
collagen-induced arthritis (CIA) in a random sample (more
than 50) of the large, outbred rhesus monkey colony at our
institute (more than 1,200 animals) appeared heterogeneous,
as is observed for human RA. In about half of randomly
selected animals from the outbred colony of genetically typed
rhesus monkeys at our institute, CIA could be induced. On
the basis of these data, the CIA model in rhesus monkeys
was further developed as a preclinical model of human RA.
The rhesus monkey model of
collagen-induced arthritis
CIA is induced in rhesus monkeys by immunization with 3 to
5 mg bovine collagen type II (b-CII) dissolved in 0.5 ml 0.1 M
acetic acid and emulsified in an equal volume of complete
Freund’s adjuvant (CFA). This emulsion is injected into the
dorsal skin, distributed over 10 spots to reduce the formation
of ulcerative skin lesions.
The time of onset and severity of clinical signs varies, most
likely reflecting the outbred nature of the colony. Whereas RA
susceptibility, more precisely the disease severity, in the
human population maps to the major histocompatibility
complex (MHC) class II alleles HLA-DR1 to HLA-DR4, no
apparent association with the MHC class II region has been
observed in rhesus monkeys thus far. This was rather
unexpected, because ‘shared epitopes’ that confer a high risk
to RA (QKRAA and QRRAA) are present at the correct
location in several Mamu-DRB1 alleles (see the IPD-MHC
sequence database [20]). In contrast, a strong influence of
the MHC class I region on the susceptibility to CIA was
found. Young animals (of Indian origin) from our colony that
were positive for the Mamu-A26 serotype appeared
completely resistant to the disease even after several booster
immunizations. This resistance may be age dependent, since
Mamu-A26+ monkeys more than 20 years old developed CIA,
though the disease was less severe than in animals lacking
this marker. Furthermore, the resistance is specific for the
immunizing antigen, since Mamu-A26+ and  Mamu-A26–
monkeys are equally susceptible to experimental autoimmune
encephalomyelitis (EAE) induced with human myelin basic
protein (Table 1). Selection of A26– monkeys thus allows
reproducible induction of CIA in >95% of animals.
Furthermore, the Mamu-A26-associated CIA resistance was
mainly observed in rhesus monkeys of Indian origin (B ‘t Hart,
RE Bontrop, personal observation). We recently found that
the A26 serotype defines a region configuration encoding
multiple Mamu-B molecules, which has been renamed Mamu-
B26 [21]. Hence it is possible that this resistance is defined
by a particular combination of MHC class I molecules or by a
closely linked gene. A gender bias as observed in humans for
the risk of developing RA was not found for CIA in rhesus
monkeys, although a prevalence in females has been found in
the closely related cynomolgus macaque.
Biomarkers for inflammation and joint
destruction
Several surrogate markers for CIA have been developed,
which reflect different pathological aspects of the model, that
is, markers for inflammation, bone degradation, and clinical
wellbeing. These markers help to determine the therapeutic
efficacy of a new therapy. Consistent improvement of a
biomarker in the experimental group versus a control group
without a direct clinical effect can nevertheless indicate a
therapeutic effect. The relation between various biomarkers,
the clinical manifestation of arthritis in the model, and the147
response to treatment is illustrated by data collected over the
past decade.
Serum CRP as a biomarker of CIA severity
The serum level of C-reactive protein (CRP), an acute-phase
protein produced in the liver under conditions of systemic
inflammation, is increased in patients with clinically active RA
[22]. A low but significant increase of serum CRP concen-
tration can be observed years before the onset of RA
symptoms [23]. This protein is a very useful marker of
inflammation and a potential biomarker for the anti-
inflammatory effect of a new therapy, because the half-life
remains unchanged under conditions of health and disease.
Moreover, the serum CRP concentration directly reflects the
intensity of the pathological process. After a small increase of
CRP in the first week after CIA induction without clinical signs,
a second increase is observed in CIA-sensitive animals, which
is more pronounced and precedes the onset of clinical
arthritis. In the CIA model, CRP is elevated before
macroscopic clinical signs are observed and can be used as
an early marker for disease onset. On the basis of the CRP
pattern, three types of CIA responders are discerned in an
outbred animal group: group I animals (n = 6) are early
responders, showing an increase in CRP above an arbitrary
threshold of 50 mg/l before day 14. Group II animals (n = 12)
are moderate responders, showing an increase in CRP above
50 mg/l between days 14 and 21. The third group (group III;
n = 13) are late responders, showing an increase in CRP of
more than 50 mg/l between days 21 and 35. The highest peak
CRP levels were observed in the early responders (Fig. 1, top
panel, squares); the lowest, in the late responders (circles).
Body weight as a general disease marker
Early CIA responders display a rapid weight loss between
days 14 and 28 (Fig. 1, panel 2). In early experiments, those
monkeys that were not humanely killed at the height of the
disease showed, after a disease episode of variable length, a
body weight increase that was associated with remission of
clinical signs of arthritis, such as pain or apathy. Hence, body
weight is a useful objective biomarker of the general disease
status.
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Table 1
Young Mamu-A26+ rhesus monkeys are sensitive to collagen-
induced arthritis
Collagen-induced Experimental  autoimmune 
arthritis encephalomyelitis
Serotype Positive Negative Positive Negative
A26+ 2965
A26– 25 3 9 3
P < 0.0001 P < 0.31
Figure 1
Clinical and hematological markers of collagen-induced arthritis. 
(Top panel) Early responders to challenge (group I, square points)
demonstrated a sharp and larger increase in C-reactive protein (CRP)
than was observed for intermediate and late responders (respectively,
group II, triangles; and group III, circles). (Panel 2) Animals with an
early increase in CRP showed an early weight loss. Group III showed
only a minor weight loss after day 28. The hematocrit values (panel 3)
were decreased during periods of active inflammation, while platelets
(panel 4) and neutrophils (panel 5) were increased Each data point in
the graphs represents a mean value for at least 3 animals for group I
(n = 6) and 5 animals for groups II and III (n = 12 and n = 13,
respectively). Squares, early responders (group I); triangles,
intermediate responders (group II); circles, late responders (group III).148
Hematological and chemical markers of disease
Neutrophils, platelets, hematocrit
Once a week, a complete hematological and serological
analysis is performed, which provides additional information
on the disease status and the general physical condition. An
increase of platelets and neutrophils marks episodes of active
inflammation (Fig. 1, panels 4,5). Furthermore, active periods
of the disease are associated with decreased hematocrit
values (Fig. 1, panel 3).
Albumin and alkaline phosphatase alkaline phosphatase
The production of the serum protein albumin is affected by the
induction of acute-phase proteins such as CRP (Fig. 2, top
panel). Predictably, serum levels of albumin are found to be
decreased during active joint inflammation (Fig. 2, panel 2).
Alkaline phosphatase (AP) is a marker for the evaluation of
bone metabolism. AP is mainly produced in the liver and by
osteoblasts. When liver enzymes are unaltered, changes in AP
can be indicative of increased bone metabolism as a
consequence of ongoing destructive joint erosion (Fig. 2,
panel 3).
Urinary excretion rates of collagen cross-links as a biomarker
of joint erosion
Joint tissues contain different quantities of the major cross-
links hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP),
which are degradation products of collagen contained in
cartilage and bone and are excreted into the urine. Urinary
excretion rates of these metabolites can therefore serve as
biomarkers of joint destruction. About 95% of the cross-links
in the joint cartilage of the rhesus monkey consists of HP
(HP/LP ratio = 55), while the HP/LP ratio in bone is 3.8 [24].
As the excretion rate of the cross-link product varies during
the day, urine samples for analysis were collected overnight
and stored frozen at –20°C. Unhydrolyzed urine samples
were used for the measurement of collagen cross-links with
reverse-phase high-performance liquid chromatography
(HPLC) essentially according to the method of Black and
colleagues [25]. Increased excretion rates of HP and LP,
expressed relative to creatinine, were observed during the
active phase of CIA (Fig. 2, two lower panels). In particular,
the excretion rates of HP were associated with CIA severity.
A fivefold increase in the HP/Cr ratio relative to baseline
values (from about 200 to 1,000) was observed in early
responders (group I). The LP excretion rate followed the
same course but increased only twofold (from about 45 to
100), suggesting a prominence of cartilage degradation. The
HP excretion rate correlated with the number of affected joints
per animal in each group. In the early responders, the mean
number of affected joints was approximately 26. It was lower,
(approximately 16) in group II, and lowest (10) in group III.
Immunological evaluation: collagen specific IgM and IgG
A clear contribution of autoantibodies to the immuno-
pathogenesis of CIA was found in arthritic animals. The
resistance to CIA observed in Mamu-B26 (formerly A26)-
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Figure 2
Serological and urinary markers of collagen-induced arthritis. 
(Panel 2) The serum albumin concentration was negatively correlated
with the production of acute-phase proteins such as C-reactive protein
(CRP) (top panel). (Panel 3) Alkaline phosphatase (AP) is mainly
produced by liver and osteoblasts. When liver function is normal,
changes in AP can be indicative of bone remodeling processes as a
result of bone degradation. (Panels 4,5) Increased urinary excretion
rates of hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP) cross-
link products, expressed relative to creatinine (Cr), were observed
during the active phase of the disease. Each data point in the graphs is
a mean of at least 3 animals for group I (n = 6) and 5 animals for
groups II and III (n = 12 and n = 13, respectively). Squares, early
responders (group I); triangles, intermediate responders (group II);
circles, late responders (group III). 149
positive animals is most likely associated with the failure to
produce adequate levels of immunoglobulin (Ig)M antibodies
against the immunizing antigen [26,27]. Interestingly, CIA-
resistant animals mount a normal collagen-specific IgG
response, both quantitatively and qualitatively, that is,
reactivity profile with epitopes in the CB11 fragment of
collagen [28]. Unpublished data indicate that the subclass of
anticollagen IgG antibodies in resistant monkeys may
resemble human IgG4, which does not efficiently fix
complement. As the IgG4-like antibodies bind to the same
epitopes as the complement-fixing IgG1/3-like antibodies in
CIA-susceptible animals, these IgG4-like antibodies may
protect the joint cartilage against opsonization.
Histology of CIA-affected joints.
For routine histology, the patellae of both knee joints and the
proximal interphalangal and distal interphalangeal joints of the
third digit of the hand and foot were processed and analyzed.
Figure 3 shows different phases of the destructive erosion of
cartilage and subchondral bone in an arthritic finger joint. We
use the pathology grading system published by Pettit and
colleagues [29]. This system quantifies the degree of
inflammation, bone destruction, and cartilage degradation on
an arbitrary scale from 0 to 5.
The arthritic joints of CIA-affected rhesus monkeys display
essentially the same histopathological hallmarks as RA joints.
In the early phase of active CIA, hyperplasia of the synovium
and pannus formation were already observed [30]. These
preceded the dramatic destruction of cartilage and bone in
advanced CIA (Fig. 3, bottom left).
Ethical management
The ethical management of the rhesus monkey CIA model
relies on a semiquantitative clinical scoring system that
represents the overall disease status of the animals (Table 2).
Clinical signs that were monitored daily are body weight, body
temperature, and the amount of pain relief used. Macroscopic
signs of inflammation, that is, the number of joints showing soft-
tissue swelling, warmth, and redness, were recorded twice
weekly. Medication to minimize the discomfort during the
experiment was given at the indication of the institute’s
veterinarians. Pain relief medication consisted of buprenorphine
(Temgesic; an opiate). Ulcerative skin lesions developing at the
immunization sites were sprayed daily with disinfectant wound
spray (Acederm) to prevent further contamination.
Prophylactic treatment with a promising compound can result
in a marked reduction of the clinical score, signifying
improved clinical wellbeing, as was recently described for a
low-molecular-weight CCR5 antagonist [31].
All these markers can be used to evaluate various aspects of
the disease, allowing us to differentiate between disease-
modifying drugs affecting bone degradation or therapies
affecting inflammation.
Pathogenic mechanisms in CIA
The variety of intervention studies performed in the past
decade have provided insight into the pathogenic mechanisms
operating in the rhesus monkey CIA model. As proposed for
RA by Choy and Panayi [1], we like to distinguish three phases
in the etiopathogenesis of the CIA model (Fig. 4).
Synovitis
As in RA, a hyperplastic synovium staining positively for
CD3+ and CD68+ infiltrated cells can be found in joints
lacking macroscopic signs of arthritis [30]. When the
hyperplastic synovium is removed — for example, by intra-
articular injection of thymidine-kinase-expressing adenovirus
followed by gancyclovir infusion — joint inflammation is
abolished [32]. This finding illustrates that similar to RA, CIA
probably starts with synovitis.
Leukocyte infiltration
Histological analysis of arthritic joints has revealed the
presence of several leukocyte subsets, such as T cells, B
cells, macrophages, and neutrophils. Lymphocyte migration
to the site of inflammation is directed by chemokines. Effector
T helper type 1 (Th1) cells expressing chemokine receptors
CCR5 and CXCR3 have been found enriched in synovial
joints of RA patients. Ligands for both chemokine receptors
are elevated in inflamed synovial tissue and synovial fluid [33-
35]. A low-molecular-weight CCR5 antagonist that prevents
the binding of its ligand, and hence the migration of these
destructive T cells, was tested in the CIA model of rhesus
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Figure 3
Histology of a proximal interphalangeal joint, showing phases of the
degenerative process in CIA. (Top left) A healthy, unaffected joint in a
rhesus monkey with collagen-induced arthritis (CIA) shows intact
cartilage and no marked activity of the subchondral bone. 
(Top right) Joint destruction starts where the synovium overgrows the
cartilage. A hyperplastic synovium resulting in pannus formation
produces factors such as cytokines and matrix metalloproteases
mediating the destruction of the cartilage. (Bottom left) In the late
phase of the disease, cartilage can be completely eroded and also the
underlying bone can be seriously damaged.150
monkeys. Prophylactic treatment with this compound resulted
in diminished severity of disease compared with that in
nontreated controls [31] and in better control of several
disease markers, such as serum levels of CRP and body
weight (Fig. 5a,b), serum albumin and alkaline phosphatase
(Fig. 5c,d), and the urinary excretion rates of the collagen
cross-link products HP and LP (Fig. 5e,f).
T cells
The role of T cells in the onset of CIA in rhesus monkeys was
shown in two separate studies. Early treatment with ciclosporin
A, a strong inhibitor of T-cell immunity, prevented the
development of CIA [36]. However, treatment of animals during
clinically active CIA had no effect on the disease. In a separate
study we showed a beneficial effect of daclizumab, a
humanized antibody directed against the Tac antigen on the IL-
2 receptor α chain [37]. Both studies underline that T cells
present in the early inflammatory synovium play an important
role in the onset of arthritis. The poor proliferative response of
rhesus monkey blood mononuclear cells to CII has hampered
the generation of stable cell lines. Hence, the precise
specificity analysis and MHC restriction of cellular autoimmune
mechanisms could not be systematically evaluated.
Neutrophils
Activated neutrophils produce highly toxic reactive oxygen
species that destroy tissue inhibitors of metalloproteases
(TIMPs) and thus make the joint more vulnerable to
metalloproteases [38]. Interestingly, early treatment of CIA-
affected rats via the drinking water with the oxidative-burst
antagonist apocynin protects against the arthritis but leaves
T-cell (delayed-type hypersensitivity; DTH) or B-cell functions
(serum antibodies) intact [39].
Autoantibodies
A newly emerging target of therapy is the B cell, for example
using rituximab, a depleting antibody directed against CD20.
Initially used for the treatment of B-cell lymphomas, this
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Figure 4
Schematic presentation of immune factors in the arthritic process. (a) A healthy joint. The histology of a healthy rhesus monkey diarthrodial joint
resembles that of humans, namely, a thin synovium lining the synovial cavity and a rather thick layer of hyaline cartilage covering the articular bone.
No marked activity of the bone marrow is observed. (b) The early phase of collagen-induced arthritis (CIA). Synovitis with marked infiltration of T
lymphocytes and macrophages is already present in clinically unaffected joints. (c) The late phase of CIA. We have little information about this
stage of the disease, because monkeys are usually killed earlier, for welfare reasons.
Table 2
Scheme for clinical and ethical management of rhesus monkeys with collagen-induced arthritis
Disease score Characteristics Monitoring Maximal durationa
0 No disease symptoms Daily Length of experiment
0.5 Fever (>0.5°C) 2 × per week 12 weeks
1 Apathy; lessened mobility; loss of appetite Daily 10 weeks
2 Weight loss; warm extremitiesb; treatable pain without STS 2 × per weekc, or daily 6 weeks
3 Redness of joints (with STS)b; normal flexibility of extremities 2 × per week 4 weeks
4 Severe STS of joints (plus redness); joint stiffnessb 2 × per week 2 weeks
5 Untreatable pain; immobility of jointsb; weight loss >25% 2 × per weekc, or daily 18 hours
aThe duration of discomfort is calculated cumulatively. bCan be assessed only in the sedated monkey and therefore cannot be done more than
twice a week for ethical reasons. cFor characteristics requiring sedation. STS, soft-tissue swelling.151
antibody has now proven effective in the treatment of RA [40].
That collagen-specific antibodies, in particular those of the IgM
isotype, have a pivotal role in the rhesus monkey model of CIA
appears from two findings. The absence of anti-CII IgM
production in CIA-resistant monkeys is highly suggestive of a
causal link [27]. This is supported by the observation that
monkeys and rats presensitized with CII, in which
conformational B-cell epitopes had been destroyed by heating,
are protected against CIA [41]. Control animals, which had
been presensitized with albumin and subsequently immunized
with native CII in CFA, developed CIA and produced normal
anti-CII IgM and IgG antibody levels. However, the protected
animals failed to produce IgM antibodies, but produced normal
levels of anti-CII IgG antibodies.
The fine specificity of anti-CII IgG was determined by
analyzing the reactivity of immune sera from CIA-susceptible
and resistant monkeys with synthetic peptides based on the
CB11 fragment of bovine CII [28]. Sera from both groups
reacted with the same peptides, including peptide 260–273,
which contains a dominant T-cell epitope in murine CIA.
How can the role of IgM antibodies be explained? Most
binding sites of anti-CII antibodies on the surface of intact
human articular cartilage are protected by proteinaceous
material from the synovial fluid. This layer can be removed by
neutrophil elastase digestion. We believe that the CII epitope
density on the intact cartilage surface is too low for classical-
route complement fixation by bound anti-CII IgG antibodies.
However, surface binding with one of the five available
antigen-binding sites of an anti-CII IgM molecule is sufficient
for complement fixation, and neutrophil binding via Fc
receptor and/or C3 receptor can take place. Erosion of the
cartilage surface under the influence of neutrophil elastase
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Figure 5
Effect of a CCR5 antagonist on clinical, inflammatory, and bone remodeling processes of collagen-induced arthritis (CIA). CIA was induced in 10
susceptible rhesus monkeys. One group of five animals received prophylactic treatment with the low-molecular-weight CCR5 antagonist SCH-X
twice daily for 45 days by intramuscular injection, while a second group of five animals received saline solution for the same period. Treatment was
started on the day of CIA induction. Results are expressed as the mean maximum change (± standard deviation), which was deduced from the
highest measured increase or decrease of the depicted parameter relative to the start of treatment. The figure shows a significant effect (Student’s
t-test; P < 0.05) of SCH-X treatment on serum levels of C-reactive protein (CRP) (a), albumin (c), and alkaline phosphatase (AP) (d), as well as the
excretion rates of hydroxylysylpyridinoline (HP) (e) and lysylpyridinoline (LP) (f). The effect on body weight (b) was not statistically significant.
Histology confirmed the lower-joint destruction in the group treated with SCH-X (see ref [31]).152
enhances the exposure of antibody-binding sites on collagen
and other cartilage antigens. It can thus be envisaged that
IgG antibodies can enhance inflammation and degradation of
an already affected joint [42,43].
Interferon β
The current state-of-the-art biological treatment in RA is with
inhibitors of proinflammatory cytokines such as TNF-α and
IL-1. We have not directly tested antagonists of these
cytokines in the model, as treatments that have already been
approved for use in patients are usually not tested in
nonhuman primates. However, we have tested mammalian-
cell-derived IFN-β. This interferon inhibits the production or
the effects of proinflammatory cytokines such as IL-12. It also
inhibits the secretion of TNF-α and exerts a variety of
immunomodulatory effects, which underlie the therapeutic
benefit in multiple sclerosis [44].
We have tested recombinant human IFN-β (REBIF®, Ares-
Serono, Geneva, Switzerland) as a treatment for CIA in four
rhesus monkeys. At the tested dose of 107 units per day
administered via subcutaneous injection during one week, the
cytokine showed a clear beneficial effect on clinically
manifest arthritis in two monkeys and abolished arthritis in
one monkey [45]. A clinical trial in RA patients of fibroblast-
derived IFN-β (Frone®, Ares-Serono) combined with
methotrexate failed to reproduce the promising effects of IFN-
β observed in the monkeys [46], but negative interaction of
the two medications cannot be excluded.
Towards a treatment for chronic inflammation
In the later stages of the disease, the cartilage is severely
damaged, requiring repair of the damage for restoration of
function. A possible strategy to treat this condition is the
introduction of a matrix that provides a scaffold for chondro-
cytes and that stimulates the regeneration of the cartilage.
The main obstacle will be the introduction of such a matrix
under inflammatory and destructive conditions. Conceptually,
the regenerating substrate not only provides a scaffold for
rebuilding the cartilage but also provides immunomodulatory
signals that help to restore homeostatic mechanisms
maintaining tolerance to joint antigens. Implantation of a
tolerogenic collagen matrix, for example, would obviate the
need for further immunosuppressive regimens.
A still-unresolved question is why the inflammation in RA is
chronic. We have postulated a model in which the dendritic
cell (DC) plays a pivotal role in governing the response to
released self-antigens. The reasoning is that DC maturation is
regulated by the interaction of C-type lectin receptors
(CLRs), binding glycan epitopes on self-antigens and
pathogens, and Toll-like receptors (TLRs), which recognize
conserved molecular patterns on pathogens [47]. This notion
has led to the Yin–Yang hypothesis for the regulation of
autoimmunity and tolerance by DCs [48]. In the concept,
testable hypotheses were formulated for the maintenance of
tolerance to self-antigens in a resting immune system and the
induction of reactive or chronic inflammation by infection. The
three depicted paradigms mentioned below describe extreme
situations. In clinical reality, subtle variants may occur.
One paradigm, the tolerance paradigm, postulates that in a
resting immune system, immature DCs present in lymhoid
organs, and their equivalents in the joint, such as the type A
synovial lining cells, continuously sample glycoproteins
released from the normal tissue turnover via their CLRs.
When presented in the absence of DC maturation signals, T
cells recognizing the presented glycoproteins attain a
regulatory function. By this mechanism, the nonresponsive-
ness of the immune system is maintained. This mechanism
may explain why a pig collagen matrix implanted into the knee
joint of a healthy rhesus monkey does not evoke anticollagen
autoimmunity (our own unpublished observations). In
addition, the robust tolerance that is induced when rhesus
monkeys are pretreated with attenuated collagen in
incomplete adjuvant — that is, in the absence of a TLR ligand —
may be explained by this model. Interestingly, the observation
that rats injected with T cells from rats immunized with
attenuated CII produced lower anti-CII antibody levels
suggests a regulatory function of the transferred cells [41].
The infection paradigm postulates that disturbance of the
CLR/TLR balance by a viral or bacterial infection induces DC
maturation. Consequently, self-antigens sampled by the DCs
will be presented in the context of costimulatory signals
expressed by mature DCs and induce Th1 cell activation.
Immunohistochemical analysis of the arthritic joints of RA
patients reveals that high quantities of the TLR2/Nod1,2
ligand peptidoglycan are present in the arthritic joint [49].
Peptidoglycan is arthritogenic by itself in susceptible rodent
strains and can enhance a specific autoimmune reaction to
central nervous system myelin, giving rise to monophasic
autoimmune encephalomyelitis [50]. Importantly, when the
TLR stimulus is cleared, the CLR/TLR balance is restored,
and tolerance can be restored by the induction of regulatory
T cells (Treg) specific for joint components. This paradigm
could explain why in monkeys that have recovered from CIA it
is almost impossible to induce exacerbation of the arthritis by
a second immunization with bovine collagen type II [26,51].
Another paradigm is that of altered glycosylation. Glycosylation
is the most important post-translational modification of
secreted proteins, which are expressed on the cell membrane
or part of the extracellular matrix. Glycosylation of self-
glycoproteins is not constant, but varies with time (ageing) and
place (organ-specific glycosylation). Moreover, the normal
glycosylation patterns can change under pathological
conditions that cause stress to cells, such as infection, or on
exposure to certain hormones or cytokines [52,53]. The
disturbance of the normal glycosylation under these conditions
may affect the restoration of the delicate CLR/TLR balance
after clearance of the TLR ligand and thus impair remission of
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the inflammation. RA is one of the clinical disorders in which
abnormal glycosylation of self-antigen (agalactosyl IgG) has
been suggested as a cause of autoimmunity [54]. It was shown
in a mouse CIA model that the arthritogenic and tolerogenic
capacity of CII depends on the glycosylation of the immunizing
autoantigen. We hypothesize that the disturbed glycosylation
may not be confined to IgG but may also affect other self-
antigens in the joint, such as CII.
Future perspectives
CIA in rhesus monkeys is a very useful preclinical model of
human arthritis, but it is suboptimal in a number of respects.
First, the arthritis can be very severe. In addition, the large
size of the monkeys, which weigh 6 to 10 kg at adulthood, is
an advantage for blood collection or invasive techniques
(arthroscopy). However, this implies that large amounts of
test compound are required to observe a clinical effect.
Another disadvantage of using CIA in rhesus monkeys is the
aggressive nature of these monkeys, which usually have to be
sedated for each handling, limiting the frequency of
experimental interventions. Moreover, the model is usually
monophasic, although in some cases exacerbation could be
induced by booster immunization [26]. Finally, because of the
high susceptibility to mycobacterial components of adjuvant,
rhesus monkeys develop severe ulcerating skin lesions where
the CII/CFA inoculum is injected.
We have encountered similar phenomena with the rhesus
monkey EAE model, which was developed as a model of
multiple sclerosis [37]. To overcome this problem, we have
developed an EAE model in a New World nonhuman primate
species, the common marmoset [55]. This is a small animal
(weighing approximately 400 g), which is ideal for efficacy
testing in an early development phase of a new drug, when
only limited amounts of the compound are available. The new
EAE model appeard to lack all the negative aspects of the
rhesus monkey EAE models and to represent the human
disease multiple sclerosis much better. A unique aspect of
marmosets is that they normally give birth to nonidentical
twins or triplets, which, because they share the placental
bloodstream, are complete and stable bone marrow
chimeras. The resulting allo-tolerance between twins allows
the exchange of cells and tissues without rejection. We
expect that the same differences observed for the EAE
models also hold true in CIA and have started to explore the
susceptibility of marmosets to arthritis induction with bovine
collagen type II. Whether the success of the marmoset model
for multiple sclerosis can be reproduced in RA will become
clear in the coming years.
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